ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC
NCT05198154 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-04-23
Summary
This study aims to explore the correlation of circulating tumor DNA(ctDNA) and the risk of progression in patients with advanced NSCLC who have long-term benefit from first-line immunotherapy (PFS 12 months)
Conditions
- Advanced Lung Non-Small Cell Carcinoma
Interventions
- DIAGNOSTIC_TEST
-
ctDNA detection
High-depth sequencing method is used to detecting ctDNA.
Sponsors & Collaborators
-
Sun Yat-sen University
collaborator OTHER -
First Affiliated Hospital Xi'an Jiaotong University
collaborator OTHER -
Fujian Cancer Hospital
collaborator OTHER_GOV -
Third Affiliated Hospital of Third Military Medical University
collaborator OTHER -
Xiangya Hospital of Central South University
collaborator OTHER -
Qinghai Province Tumor Hospital
collaborator UNKNOWN -
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
collaborator OTHER -
Zhejiang Provincial People's Hospital
collaborator OTHER -
Hunan Province Tumor Hospital
collaborator OTHER -
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
collaborator OTHER -
Second Affiliated Hospital, School of Medicine, Zhejiang University
collaborator OTHER -
Zhejiang Cancer Hospital
collaborator OTHER -
The First Affiliated Hospital of Guangzhou Medical University
collaborator OTHER -
Inner Mongolia People's Hospital
collaborator OTHER -
Guizhou Provincial People's Hospital
collaborator OTHER -
The Third Xiangya Hospital of Central South University
collaborator OTHER -
Yueyang Central Hospital
collaborator OTHER -
ZhuZhou Central Hospital
collaborator OTHER -
Zhangjiajie Affiliated Hospital of Hunan Normal University
collaborator UNKNOWN -
Loudi Central Hospital
collaborator OTHER -
Chang Sha First Hospital
collaborator UNKNOWN -
Fang Wu
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-01-24
- Primary Completion
- 2025-12-30
- Completion
- 2025-12-30
Countries
- China
Study Locations
More Related Trials
-
Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung Cancer
NCT05425134 ·Status: UNKNOWN
-
Multiplex Analysis of Circulating Tumor DNA
NCT03301961 ·Status: UNKNOWN
-
Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC
NCT04984148 ·Status: UNKNOWN
-
Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients
NCT03664843 ·Status: UNKNOWN
-
ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS
NCT03465241 ·Status: COMPLETED
-
Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer
NCT03512847 ·Status: COMPLETED
-
Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.
NCT04720339 ·Status: RECRUITING ·Phase: NA
-
Circulating Tumor DNA Methylation Test to Differentiate Benign and Malignant Pulmonary Nodules
NCT03181490 ·Status: COMPLETED
-
Circulating Tumor DNA in Surgical Lung Cancer Patients
NCT03081741 ·Status: UNKNOWN
-
The PREDICT Study: Prospective Early Detection In a Population at High-risk for Common Malignant Tumor
NCT04405557 ·Status: ACTIVE_NOT_RECRUITING
-
Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer
NCT02645318 ·Status: COMPLETED
-
Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules
NCT03651986 ·Status: UNKNOWN
-
The Role of ctDNA Testing Plus AI-based Pathology in Resectable LSCC
NCT05778253 ·Status: RECRUITING
-
Chromosomal Instability as a Surrogate Biomarker of Drug Resistance in Immunotherapy for Lung Cancer Patients
NCT04203095 ·Status: UNKNOWN
-
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
NCT05965024 ·Status: RECRUITING
-
Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC Patients
NCT05129462 ·Status: COMPLETED
-
Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer
NCT04749407 ·Status: UNKNOWN
-
Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan
NCT06358222 ·Status: RECRUITING
-
Circulating Tumor DNA in Patients at High Risk for Lung Cancer
NCT02715102 ·Status: TERMINATED
-
Evaluation ctDNA in Patients of Non-Small-Cell Lung Cancer Following Resection
NCT04238130 ·Status: COMPLETED
-
Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy
NCT03578185 ·Status: RECRUITING
-
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
NCT03791034 ·Status: RECRUITING
-
Analysis of Deoxyribonucleic Acid and Ribonucleic Acid Next-Generation Sequencing in Non-Small Cell Lung Cancer Patients Without Pathological Complete Response Following Neoadjuvant Immunotherapy
NCT07179445 ·Status: NOT_YET_RECRUITING
-
Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients
NCT05066945 ·Status: NOT_YET_RECRUITING
-
irAE Prediction of Anti-PD-1/L1 in Lung Cancer
NCT05288569 ·Status: UNKNOWN